Bio-Rad Laboratories, Inc (BIO) Fair Value & Analysis
Healthcare · US · Market cap $8.1B
Bio-Rad Laboratories, Inc
BIO · US
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 21 days ago
Share price +24.2% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from $248.56 (bear) to $414.26 (bull), base $331.41. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 67/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range $216.56 – $825.77 · fair‑value band $248.56 – $414.26 · the $352.47 price screens above the $331.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Bio-Rad Laboratories, Inc (BIO) currently trades at $352.47, while our model-based Fair Value estimate is $331.41, implying the stock looks roughly 6.0% fairly valued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Bio-Rad Laboratories, Inc generated revenue of $2.6B at a net margin of 6.5%. Revenue grew 1.1% year over year. It earns a return on equity of 2.5%. Net debt stands at $999M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $248.56 (bear case) to $414.26 (bull case); at $352.47, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades near its 52-week high and 60% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -6%, BIO screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings ($649.56) versus Economic Profit ($34.68). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
Full company description
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bio-Rad Laboratories, Inc reported revenue of $2.6B in FY2025 versus $2.9B in FY2021, a compound −3.0%/yr. Reported net income was $760M in FY2025, compounding −35.0%/yr from FY2021.
Watch BIO: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary
- Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ...
- Bio-Rad forecasts 2026 currency-neutral revenue growth of (-3%) to +0.5% while targeting $30M-$35M net cost savings by end of 2027
- Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Bio-Rad Laboratories, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bio-Rad Laboratories, Inc (BIO) overvalued or undervalued?
What is the fair value of BIO?
What is the quality score of BIO?
What is the revenue of Bio-Rad Laboratories, Inc (BIO)?
What is the net profit margin of BIO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bio-Rad Laboratories, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.